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Abstract
The nonsteroidal antiinflammatory drugs (NSAIDs) indomethacin and salicylic acid and the short chain fatty acid
butyrate are effective colon cancer chemopreventive agents that increase reactive oxygen species (ROS) generation in colon
cancer cells. Here we demonstrate that these agents sensitize the normally resistant human HT-29 colon cancer cell line to
apoptosis induced by TNF-K or a Fas ligating antibody. The role of ROS in this sensitization is supported by the finding that
direct exposure of the cells to H2O2 is sufficient for sensitization. Neither TNF-K nor Fas ligation alter basal or
chemopreventive agent-activated ROS generation, suggesting that the death ligands and chemopreventive agents act in a
complementary fashion. The dual chemopreventive agent/death ligand treatments do not increase Fas, TNF receptor 1, Bak
or c-myc expression (although salicylic acid moderately induces of Fas expression). Cell death does correlate with alterations
in NF-UB activity : the NSAIDs, butyrate and H2O2 enhance c-Rel complex formation by TNF-K and provide an overall
enhancement of NF-UB activation by Fas. The antioxidant N-acetylcysteine (NAC) blocks cell death and NF-UB activation
induced by Fas ligation, suggesting a potential role for NF-UB in Fas-induced apoptosis in these cells. The effects of NAC on
TNF-K-induced cell death are more complex, with NAC being marginally protective and itself enhancing the formation of
c-Rel containing complexes at higher concentrations (25 mM). The influence of NSAIDs and butyrate on ROS generation
and death ligand sensitivity may be relevant to their ability to suppress colon carcinogenesis. ß 1999 Elsevier Science B.V.
All rights reserved.
Keywords: Reactive oxygen species; Cancer; Nonsteroidal antiin£ammatory drug; Butyrate; Apoptosis; Tumor necrosis factor-K ; Fas;
NF-UB
1. Introduction
The proper functioning of many tissues requires an
intricate balance between cell proliferation and pro-
grammed cell death (apoptosis). Healthy colonic epi-
thelium is an excellent example of a tissue that main-
tains such an equilibrium. Cells derived through cell
division at the crypt base migrate towards the surface
of the lumen where they undergo apoptosis and are
shed from the tissue. If the level of cell death is too
low, pathological conditions such as colon cancer
may occur [1]. Excessive cell death may lead to dis-
ease states such as ulcerative colitis [2]. Understand-
ing how cell death in colonic tissue is regulated could
lead to improved treatments and prevention strat-
egies for cancer and other diseases.
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The regulation of cell death in the epithelium of
the colon and large intestine are likely to involve a
number of signaling systems including the loss of
cell-substrate interactions [3,4], and autocrine pro-
duction of the transforming growth factor-L (TGF-
L) [5]. The luminal short chain fatty acid butyrate
may also play a role in regulating apoptosis [6],
although data has also been obtained suggesting
that it serves as an energy source for cells under
certain culture conditions [7]. The concept of buty-
rate as a regulator of cell death in the colon is con-
sistent with the ¢nding that it can suppress colon
carcinogenesis [8]. The role of TNF-K and Fas ligand
in regulating cell turnover in the colonic epithelium
under normal conditions is not well understood.
Normal colonocytes display the Fas receptor on their
basolateral surface membrane [9], and Fas ligand is
expressed by a subpopulation of cells of the lamina
propria [10]. During pathological conditions, the
presence of these cytokines is increased, probably
due to the in¢ltration of immune cells. In ulcerative
colitis, Fas ligand-expressing in£ammatory cells have
been shown to greatly increase in number [2,10].
TNF-K levels in the mucosa can also increase under
conditions that induce ulceration [11]. In addition,
TNF-K is detected in cancerous tissue, where its pres-
ence correlates with a favorable prognosis [12,13].
Understanding how and when di¡erent death induc-
ing systems are mobilized in the intestinal mucosa,
and how the cellular responses to these signals are
regulated, is a complex and important research chal-
lenge.
Reactive oxygen species (ROS) can play a central
role in regulating cell proliferation and cell death.
Evidence has been obtained that reactive oxygen
species such as superoxide and hydrogen peroxide
can in£uence cell death triggered by internal cues
(p53-mediated) [14], external cues (TGF-L-mediated)
[15^17] and immunogenic signals (TNF-K and Fas
ligand) [18^22]. It is therefore possible that ROS
play a role in regulating apoptosis in colonic epithe-
lium. To begin exploring this possibility, we recently
determined the e¡ect of a number of chemical agents
implicated in inducing cell death in the colon for
their e¡ects on ROS production. Speci¢cally, we de-
termined the e¡ects of nonsteroidal antiin£ammatory
drugs (NSAIDs) and short chain fatty acids in the
moderately well di¡erentiated HT-29 human colon
cancer cell line [23,24]. NSAIDs have been demon-
strated to reduce the risk of colorectal cancer, poten-
tially by accentuating apoptosis of transformed cells
[25]. In addition, NSAIDs exacerbate ulcerations in
the colon, probably by accentuating cell death [26].
Short chain fatty acids derived from dietary ¢ber
that may reduce colon cancer risk by accentuating
cancer cell apoptosis were also analyzed [24,27,28].
It was found that all these agents could accentuate
ROS generation in HT-29 cells [29]. Here we describe
how this increased ROS generation in£uences cell
sensitivity to death ligands, and how cell death signal
transduction may be a¡ected.
2. Materials and methods
2.1. Chemicals
Indomethacin, N-acetylcysteine (NAC; neutralized
with NaOH), H2O2, and butyric acid (neutralized
with NaOH) were purchased from Sigma. Salicylic
acid was purchased from Fisher, and dihydrodichlo-
ro£uorescein (H2DCF; diacetate form) from Molec-
ular Probes (Eugene, OR).
2.2. Antibodies and cytokines
The following antibodies were used in the de-
scribed studies: anti-Fas clone DX2.1 from RpD
Systems for immunoblotting, anti-Fas clone from
Kamiya for the induction of apoptosis, anti-TNF
receptor 1 clone 16803.1 from RpD Systems, anti-
NF-UB p50 Ab-1 from Calbiochem, anti-RelA Ab-1
from Calbiochem, anti-c-Rel Ab-1 from Calbiochem,
anti-c-myc N-262 from Santa Cruz, and anti-Bak G-
23 from Santa Cruz. Recombinant human TNF-K
was obtained from RpD Systems.
2.3. Cell culture and cell death assay
HT-29 cells were purchased from American Type
Culture Collection (Rockville, MD) and were propa-
gated on tissue culture plastic with McCoy’s 5A me-
dium supplemented 10% fetal bovine serum, non-es-
sential amino acids, streptomycin (50 Wg/ml) and
penicillin (50 U/ml) [29]. All medium components
were purchased from Life Technologies (Gaithers-
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burg, MD). For the cell death assays, cells were
plated on 96 well plates and grown for 2^4 days to
approximately 90% con£uency (V5U105 cells per
well). Following treatment, cell death was deter-
mined by counting the number of £oating cells per
well (after gentle mixing) with a hemacytometer. This
technique is commonly used for quantifying cell
death in HT-29 cells and other cell lines of epithelial
origin [6,30,31]. Analysis of DNA fragmentation by
gel electrophoresis indicates that the majority of
apoptotic cells are in the £oating cell population
(Fig. 1). This method is, however, semiquantitative
since a fraction of the attached cell population stain
positively with propidium iodide. For propidium io-
dide analyses, cells were stained with 50 Wg/ml propi-
dium iodide for 30 min, after which the cells were
analyzed by £uorescence microscopy. The assay for
DNA laddering involved DNA isolation by organic
extraction, degradation of RNA by RNase A treat-
ment, and electrophoresis of DNA on 1% agarose/
TBE gels.
2.4. H2DCF oxidation assay for peroxide
For the measurement of H2DCF oxidation to £u-
orescent dichloro£uorescein (DCF), cells were grown
to near con£uency on a 96 well tissue culture plate,
and loaded with H2DCF by adding the diacetate
form of this compound to the medium at a ¢nal
concentration of 50 WM [29]. After 30 min, the me-
dium was completely removed, and 100 Wl of fresh
medium was added to each well. After addition of
test agents, DCF production was detected with a
Cyto£uor microplate-reading £uorimeter (PerSep-
tive) with the excitation wavelength set at 475 nm,
and the emission wavelength at 525 nm. The £uorim-
eter was set at a gain of 50 for these measurements.
2.5. Immunoblotting
25 Wg of cytoplasmic or nuclear protein (deter-
mined by Bio-Rad protein assay) were resolved on
10% SDS polyacrylamide gels, and transferred to
nitrocellulose by voltage gradient transfer (see below
for cell fractionation protocol). The resulting blots
were blocked with 5% nonfat dry milk. Speci¢c pro-
teins were detected with appropriate antibodies using
enhanced chemiluminescence for detection, following
the manufacturers recommended protocol (Amer-
sham). C-myc and Bak were detected in the partic-
ulate, nuclear fraction, while Fas and TNF receptor
1 were present primarily in the cytoplasmic fraction.
Fig. 1. (A) The NSAIDs salicylic acid and indomethacin, and the short chain fatty acid butyrate sensitize HT-29 cells to TNF-K. HT-
29 cells grown to approximately 8U104 cells per well on a 96 well plate were treated with salicylic acid (SA; 4 mM), butyrate (BA;
4 mM), or indomethacin (IND; 200 WM) either in the presence or absence of TNF-K (TNF; 100 ng/ml). After 18 h of exposure, the
number of dead cells per well was determined. The mean and S.D. of four trials are shown. Cell death in the combination treatments
over control is signi¢cant with P6 0.01. (B) Cell death induced by TNF-K in combination with NSAIDs or butyrate is apoptotic.
DNA was prepared from dead cells (£oating cells) or live cells (attached cells) and analyzed by agarose gel electrophoresis. The ap-
pearance of a DNA ladder in the dead cell population indicates that apoptosis has occurred.
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Films resulting from the immunoblot analysis, and
other assays employed in this paper, were quanti¢ed
with a PDI scanning densitometer.
2.6. Cell fractionation
The cell fractionation protocol utilized was based
on a previously reported protocol [32]. Cells grown
on 35 mm plates were washed twice with ice-cold
PBS and incubated at 4‡C for 8 min in 250 Wl of a
bu¡er containing 0.1% NP-40 (10 mM HEPES-
KOH, pH 7.9, 10 mM KCl, 0.1 mM EDTA, 1 mM
DTT, 2 mM MgCl2, 0.5 mM PMSF, 0.5 M sucrose,
2 Wg/ml leupeptin). The cells were then scraped into
tubes and centrifuged for 10 min at 4‡C (14 000
rpm). The resulting supernatant was the ‘cytoplasmic
extract’. The resulting ‘nuclear pellets’ were rinsed
with the above bu¡er without NP-40. Nuclear ex-
tracts were prepared by resuspending nuclear pellets
in 15 Wl of a high salt bu¡er (20 mM HEPES-KOH,
pH 7.9, 1.5 mM MgCl2, 420 mM NaCl, 0.2 mM
EDTA, 1 mM DTT, 5% glycerol, 0.5 mM PMSF,
2 Wg/ml leupeptin), incubating on ice for 40 min,
and then centrifuging for 10 min at 4‡C (14 000
rpm). The nuclear extracts were then mixed with
22.5 Wl of a low salt bu¡er (20 mM HEPES-KOH,
pH 7.9, 50 mM KCl, 0.2 mM EDTA, 1 mM DTT,
20% glycerol, 0.5 mM PMSF, 2 Wg/ml leupeptin).
Protein concentrations of the nuclear and cytoplas-
mic extracts were determined by the Bradford assay
(Bio-Rad), and stored at 380‡C until used.
2.7. Electrophoretic mobility shift assay
Double-stranded NF-UB consensus oligonucleotide
(TGAGGGGACTTTCCCAGGC; Promega) was
end-labeled with Q[32P]ATP (3000 Ci/mmol at
10 mCi/ml; Amersham). Binding reactions were per-
formed by mixing 10 Wg of nuclear extract (prepared
as described above) in 10 Wl with 2 Wg poly-dIdC and
1 Wg BSA to give a ¢nal volume of 19 Wl. After a 15
min incubation on ice, 40 fmol of oligonucleotide
(1 Wl) was added to each reaction, and reactions
were transferred to room temperature for an addi-
tional 15 min [32]. Reaction products were separated
in a 4% polyacrylamide/TBE gel and the resulting
gels analyzed by autoradiography. For the supershift
experiments, polyclonal rabbit anti-RelA, anti-p50 or
anti-c-Rel antibodies (Oncogene Research Products)
were included in the binding reaction from the poly-
dIdC incubation step, and this incubation on ice was
extended to 30 min. In the RelA supershift experi-
ment, the intensity of the supershift band is less than
that of the RelA-DNA complex without antibody.
This result may be due to dissociation of the anti-
body during the gel run (leading to smearing), or an
inhibition of RelA-DNA complex formation by the
antibody. All of the complexes identi¢ed as NF-UB-
containing by the supershift assay were also speci¢-
cally competed with the NF-UB binding oligonucleo-
tide (unpublished data).
3. Results
3.1. NSAIDs and butyrate sensitize cells to TNF-K
and Fas: contribution of ROS
Our previous analysis indicated that the NSAIDs
indomethacin, aspirin, salicylate and ibuprofen stim-
ulate ROS generation in the human HT-29 cell line,
as determined by the H2DCF oxidation assay [29]. In
addition, we demonstrated a similar e¡ect of the
short chain fatty acids butyrate and propionate
[29]. Since these agents have been implicated in reg-
ulating apoptosis in the colon, we wished to deter-
mine how ROS generated by these agents a¡ect
apoptosis of HT-29 cells. We focused our e¡orts on
three compounds. The NSAIDs indomethacin and
salicylic acid were chosen for further analysis because
indomethacin is a cyclooxygenase inhibitor whereas
salicylic acid is not. The short chain fatty acid buty-
rate was chosen because it was found to be a partic-
ularly potent ROS-generating short chain fatty acid.
Initial e¡orts to determine the in£uence of NSAID
and butyrate on apoptosis of HT-29 cells were ham-
pered by the fact that these agents induced only low
levels of apoptosis. Of the three compounds under
study, only butyrate consistently triggered apoptotic
DNA fragmentation (after a 3^4 day exposure; un-
published data). We then determined whether these
agents could enhance cell death induced by receptor-
mediated routes. We ¢rst determined the in£uence of
these agents on cell killing by TNF-K. TNF-K has
been directly implicated causing tissue damage in ul-
cerative colitis [11] and studies have also implicated
BBAMCR 14423 5-1-99
C. Giardina et al. / Biochimica et Biophysica Acta 1448 (1999) 425^438428
this cytokine in suppressing tumor progression in the
colon [12,13]. As shown in Fig. 1A, HT-29 cells are
largely resistant to killing by TNF-K. This ¢nding is
in agreement with published reports from other lab-
oratories [30]. However, inclusion of indomethacin,
salicylic acid or butyrate in the incubation greatly
enhances cellular sensitivity to TNF-K (Fig. 1A).
The level of cell death in Fig. 1A was determined
after 18 h treatment and represented 30^40% of the
cultured cells exposed to the combination treatments.
To obtain evidence that cell death under these con-
ditions was apoptotic, DNA was isolated from the
£oating, dead cell population and the live attached
cells, and analyzed by agarose gel electrophoresis.
The results of this agarose gel are shown in Fig.
1B. The DNA isolated from the £oating cells dis-
plays the DNA fragmentation pattern characteristic
of an apoptotic cell death. Additional conformation
of apoptosis in the £oating cell population was ob-
tained by propidium iodide staining: for the combi-
nation treatments greater than 95% of the £oating
cells stained positively with propidium iodide. At-
Fig. 2. (A) H2O2 sensitizes HT-29 cells to TNF-K. Cells were
incubated for 18 h in the presence or absence of 100 ng/ml
TNF-K (TNF), in the presence or absence of the indicated con-
centration of H2O2. After 18 h, cell death was determined as in
Fig. 1A. The mean and S.D. of 4 trials are shown, with signi¢-
cant increases in death observed (P6 0.01). (B) Cell death by
the TNF-K/H2O2 combination treatment is apoptotic. DNA
from dead cells obtained after an 18 h incubation with TNF-K
and/or H2O2 as indicated was analyzed by agarose gel electro-
phoresis. The characteristic DNA fragmentation indicates apop-
totic cell death is occurring in the culture.
Fig. 3. (A) NSAIDs, butyrate and H2O2 enhance cell death in-
duced by a Fas ligating antibody. The HT-29 cell death assay
was performed as described in Fig. 1A, after an 18 h incuba-
tion with a Fas ligating antibody (at the indicated concentra-
tions) in the presence of the following agents: Control, no addi-
tions; SA, 4 mM salicylic acid; H2O2, 1.2 mM H2O2 ; BA,
4 mM butyrate; or IND, 200 WM indomethacin. (B) Cell death
induced by the anti-Fas combination treatments is apoptotic.
DNA from dead cells obtained after an 18 h incubation with
anti-Fas alone or anti-Fas in combination with the indicated
agents was analyzed by agarose gel electrophoresis (anti-Fas
was at 50 ng/ml; NSAIDs, butyrate and H2O2 were at concen-
trations used in (A)). The characteristic DNA fragmentation in-
dicates apoptotic cell death is occurring in the culture.
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tached cells were also analyzed by propidium iodide
staining. The dual treatments also increased the frac-
tion of attached cells that were stained with propidi-
um iodide, with the staining cells presumably repre-
senting cells at earlier stages of apoptosis. The
fraction of attached cells staining with propidium
iodide in untreated cultures averaged between 0.6
and 1.3%, with TNF-K treatment alone increasing
this number to 5^8%. Inclusion of the NSAIDs or
butyrate with TNF-K further increased attached cell
staining to 16^22%.
Previous studies indicated that all three of the che-
mopreventive agents employed in Fig. 1 increase cel-
lular peroxide generation (without increasing super-
oxide generation as determined by lucigenin-
enhanced chemiluminescence) [29]. We therefore de-
termined whether direct treatment of cells with H2O2
was su⁄cient to sensitize them to TNF-K. As shown
in Fig. 2A, HT-29 cells are largely resistant to H2O2
at 1.0 and 1.2 mM concentrations. However, these
H2O2 concentrations sensitized the cells to TNF-K.
Cell death observed in the co-treated cells was apop-
totic, as demonstrated by the appearance of a DNA
ladder in the dead cells. ROS levels provided by 1.0
and 1.2 mM H2O2 are similar to those triggered by
the NSAID and butyrate concentrations employed in
Fig. 1 ([29] and Fig. 4 below).
To determine if the NSAIDs and butyrate could
sensitize HT-29 cells to other physiological death lig-
ands, it was determined how these agents in£uence
cell killing by the Fas pathway. As shown in Fig. 3A,
HT-29 cells are largely resistant to the Fas ligating
antibody after an 18 h incubation. This ¢nding is
consistent with published reports from other labora-
tories [30], although we have noted that extended
incubation periods can result in more extensive cell
death. Inclusion of indomethacin, butyrate or sali-
cylic acid in the incubation sensitized cells to killing
by the Fas ligating antibody (Fig. 3A). Salicylic acid
is, however, consistently less e¡ective than the other
agents in sensitizing cells to Fas-mediated cell death.
The potential role of NSAID- and butyrate-induced
ROS generation in this sensitization is supported by
the ¢nding that direct treatment of the cells with
H2O2 is su⁄cient for sensitization to Fas ligation
(Fig. 3A). Cell death induced by the Fas combina-
tion treatments is apoptotic, as revealed by the ap-
pearance of the characteristic DNA fragmentation
Fig. 4. (A) TNF-K and anti-Fas do not alter ROS generation
induced by salicylic acid, butyrate or indomethacin. HT-29 cells
were loaded with H2DCF as described in Section 2. Cells were
then exposed to TNF-K or anti-Fas, in the presence or absence
of 4 mM salicylic acid (SA), 4 mM butyrate (BA), 200 WM in-
domethacin (IND) or 1.2 mM H2O2 (H2O2), as indicated. The
rate of H2DCF oxidation to DCF from 60 to 75 min after ex-
posure to the indicated treatments was determined by reading
DCF £uorescence on a £uorescent plate reader. Similar results
were obtained with pro-longed exposure to these treatments.
The average of two trials is shown. (B, C) NAC suppresses
H2DCF oxidation in cells treated with TNF-K (B) or K-Fas (C)
alone, or in combination with salicylic acid (SA), butyrate (BA)
or indomethacin (IND). Treatments were performed as in (A),
except NAC was present at 0, 12.5 or 25 mM concentrations
where indicated.
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pattern in the dead cell population (the £oating cells;
Fig. 3B). Propidium iodide staining con¢rmed that
greater than 95% of the cells in £oating cell popula-
tion were dead. Analysis of the attached cells also
indicated an enhancement of cell death by indome-
thacin, butyrate and H2O2 : in cultures treated with
Fas alone, 6^18% of the cells stained with propidium
iodide, while 18^35% of the attached cells stained
positively when sensitized with butyrate, indometha-
cin or H2O2.
In some cell types TNF-K and Fas have been
found to increase ROS generation [19^22,33]. These
death ligands might therefore sensitize cells by con-
tributing to the increased ROS generation triggered
by the NSAIDs and butyrate. To determine if TNF-
K or the anti-Fas antibody were contributing to cel-
lular ROS generation, an H2DCF oxidation assay
was performed. As shown in Fig. 4A, neither TNF-
K nor Fas increases ROS generation by HT-29 cells.
Moreover, neither cytokine alters the ROS genera-
tion triggered by the NSAIDs or butyrate (Fig.
4A). The results shown in Fig. 4 were derived after
a 1 h incubation, but similar results were obtained
when longer treatments were performed (up to 6 h;
C. Giardina, unpublished data). As shown in Fig. 4B
and C, the antioxidant NAC suppresses H2DCF ox-
idation by the NSAIDs and butyrate, consistent with
these agents enhancing ROS production. These data
are consistent with a model in which the ROS gen-
erated by the NSAIDs and butyrate complement the
cell death signal stimulated by TNF-K and Fas.
It should be noted that the H2O2 concentrations
used in this paper generate a rate of H2DCF oxida-
tion similar to those obtained by the chemopreven-
tive agents. While this concentration was chosen in
part for this similar in£uence on internal redox state,
it should be cautioned that external H2O2 applica-
tion is likely to oxidize media components more ex-
tensively.
3.2. NSAIDs, butyrate, H2O2 and death gene
activation
We have initiated an analysis to determine how
indomethacin, salicylic acid and butyrate comple-
ment TNF-K- and Fas-induced cell death signal
transduction in HT-29 cells. One mechanism by
which cells can be sensitized to these death ligands
is through the increased expression of the death lig-
and receptors. IFN-Q, for example, sensitizes HT-29
cells to Fas ligation and TNF-K by increasing expres-
sion of Fas and TNF receptor 1 [30]. As shown in
Fig. 5A, neither of the NSAIDs under study nor
butyrate enhance TNF receptor 1 expression (this
receptor participates in TNF-K-induced apoptosis
of HT-29 cells; Fig. 5B). The in£uence of the chemo-
Fig. 5. (A) The e¡ect of NSAIDs, butyrate and H2O2 on Fas
and TNF receptor 1 expression. HT-29 cells were exposed to
4 mM salicylic acid (SA), 4 mM butyrate (BA), 200 WM indo-
methacin (IND) or 1.2 mM H2O2 (H2O2), as indicated, in the
presence or absence of anti-Fas antibody (K-Fas; 50 ng/ml) or
TNF-K (100 Wg/ml). After 8 h, lysates were prepared and ana-
lyzed by immunoblotting for Fas or TNF receptor 1 (TNF
R1), as indicated. (B) TNF receptor 1 contributes to HT-29 cell
sensitivity to TNF-K. Cells were treated with the salicylic acid/
TNF-K (SA/TNF), butyrate/TNF-K (BA/TNF) or indometha-
cin/TNF-K (IND/TNF) combination treatments described in
Fig. 1, in the absence or presence of a neutralizing antibody to
TNF receptor 1 (anti-TNF R1). Cell death under these condi-
tions was quanti¢ed as described in Fig. 1.
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preventive agents on Fas expression was also deter-
mined (Fig. 5A). Of the agents under study, only
salicylic acid increased Fas expression (1.5^2.8-fold,
as determined by scanning densitometry). This in-
creased Fas expression is not likely to be ROS-medi-
ated, since H2O2 does not have this e¡ect. Since sal-
icylic acid is the least e¡ective Fas sensitizing agent,
expression of this receptor is probably not rate-limit-
ing for Fas-induced cell death. These data indicate
that the NSAID- and butyrate-induced ROS produc-
tion does not function by increasing receptor expres-
sion.
It has been reported that butyrate enhances Bak
expression in HT-29 cells, a pro-death Bcl-2 family
member expressed by colonic epithelium [34]. We
determined whether the sensitization of HT-29 cells
could be the result of increased Bak expression. As
shown in Fig. 6A, neither the individual nor combi-
Fig. 6. (A) The e¡ect of NSAIDs, butyrate and H2O2 on Bak expression in HT-29 cells. HT-29 cells were treated with salicylic acid
(SA; 4 mM), butyrate (BA; 4 mM), indomethacin (IND; 200 WM), or H2O2 (1.2 mM) in the presence or absence of TNF-K (100 Wg/
ml) or anti-Fas antibody (K-Fas) for 12 h. Cell lysates were prepared, immunoblotted and probed using a Bak speci¢c antibody. (B)
The e¡ect of NSAIDs, butyrate and H2O2 on c-myc expression in HT-29 cells. Cells were treated as in (A), only the resulting immu-
noblots were probed with a c-myc-speci¢c antibody. A 6 h time point was also generated for this experiment.
Fig. 7. (A) Salicylic acid, indomethacin, butyrate and H2O2 do not activate NF-UB DNA binding in HT-29 cells, while TNF-K and a
Fas ligating antibody do. HT-29 cells were exposed to 4 mM salicylic acid (SA), 4 mM butyrate (BA), 200 WM indomethacin (IND)
or 1.2 mM H2O2, 100 ng/ml TNF-K (TNF) or 50 ng/ml Fas ligating antibody (KFas) as indicated. After a 6 h incubation, nuclear ex-
tracts were prepared and analyzed for NF-UB DNA binding activity by EMSA. To enhance resolution of the protein-DNA complexes,
the unbound probe was run o¡ the gel. Only the protein-DNA complexes are shown. (B) Supershift analysis of NF-UB activated in
HT-29 cells. DNA binding reactions using nuclear extracts from TNF-K treated HT-29 cells were performed in the absence of anti-
body (lane marked 0), or in the presence of antibody against the p50 (Kp50) or RelA (KRelA) subunit of NF-UB. The location of the
super-shifted complex is indicated. As in (A), the free probe was run o¡ the gel.
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nation treatments increase Bak expression after 12 h
of incubation (at which time cell death can be ob-
served in the combination treatments). Longer expo-
sures to butyrate (24 and 36 h) do enhance Bak ex-
pression (unpublished data), but this increased
expression occurs too late to account for the ability
of butyrate and NSAIDs to sensitize cells to TNF-K
or Fas ligation. Increased expression of the c-myc
gene has also been implicated in NSAID-induced
cell death of transformed chick embryo ¢broblasts
[35]. As shown in Fig. 6B, none of the agents under
study increase expression of the c-myc protein in
these cells. In fact, as has been reported by others,
butyrate is a potent suppressor of c-myc expression
in HT-29 cells [24,36]. Increased c-myc expression
can therefore not account for the enhanced sensitiv-
ity of HT-29 cells to TNF-K or Fas ligation.
3.3. NSAIDs, butyrate, H2O2 and NF-UB activation
In an attempt to uncover common cellular re-
sponses to the NSAIDs and butyrate that might be
mediated by their ability to induce ROS generation,
we determined the e¡ect of these agents on the
transcription factor NF-UB. NF-UB regulates the
expression of genes involved in both the induction
of apoptosis (Fas ligand, p53 and possibly ICE)
[37^39], as well as its suppression (Mn SOD and
A20) [40,41]. While the in£uence of this transcription
factor on Fas-mediated apoptosis is not clear, a body
of work indicates that NF-UB activation protects
cells from TNF-K-induced apoptosis [44^48]. Our hy-
pothesis therefore was that the chemopreventive
agents may sensitize cells to TNF-K by inhibiting
NF-UB activation. NF-UB was also of interest be-
cause its activity is sensitive to cellular redox state
[42,43].
Fig. 7 shows the results of electrophoretic mobility
shift assays (EMSAs) used to determine the NF-UB
DNA binding activity from HT-29 cells incubated
under a number of conditions. In all cases, only
the shifted, protein-DNA complexes are shown: the
free probe is run o¡ the gel to enhance resolution of
the protein-DNA complexes. As shown in Fig. 7A,
the NSAIDs under investigation, butyrate and H2O2
fail to activate NF-UB in HT-29 cells. In contrast,
K-Fas and TNF-K do increase NF-UB binding
activity in these cells. Two predominate forms are
activated. A supershift assay demonstrates that the
bottom band is likely to be the p50/p50 homodimer,
while the top band appears to be the RelA/p50 het-
erodimer (Fig. 7B; the weaker intensity of the RelA-
supershift complex may be the result of an instability
of the antibody complex leading to dissociation
during electrophoresis). The Fas ligating antibody
also stimulates NF-UB binding in HT-29 cells, form-
ing predominately the RelA/p50 heterodimer (Fig.
7A).
We then determined if salicylic acid, butyrate, in-
domethacin or H2O2 a¡ect NF-UB activation by
TNF-K. These sensitizing agents were found to en-
hance the formation of a more rapidly migrating
band on the EMSA approximately 2.5-fold (Fig.
8A; again, only the protein-DNA complexes are
shown). This more rapidly migrating band does not
associate with antibodies against the p50 or RelA
Fig. 8. (A) Salicylic acid, butyrate, indomethacin and H2O2 in£uence the subunit composition of TNF-K activated NF-UB in HT-29
cells. HT-29 cells were treated with TNF-K alone (100 ng/ml) or TNF-K in the presence of the indicated concentrations of salicylic
acid (SA), butyrate (BA), indomethacin (IND) or H2O2. Treatments were performed for 6 h, after which nuclear extracts were pre-
pared and analyzed for NF-UB DNA binding activity by EMSA. Only protein-DNA complexes are shown. (B) A supershift assay
identi¢es c-Rel as a component of the NF-UB DNA binding activity stimulated by the NSAIDs, butyrate and H2O2. A supershift as-
say was performed using an antibody speci¢c for the c-Rel NF-UB subunit (the Kc-Rel lane). The super-shifted complex is indicated.
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subunits (as determined by supershift, data not
shown), but it is bound by an antibody against the
c-Rel subunit (Fig. 8B). Whether this complex is a
c-Rel homodimer, or c-Rel associated with another
factor (rel family member or otherwise) remains to
be determined. The increased formation of the c-Rel
complex could be the result of increased cellular
ROS production, since H2O2 also stimulates forma-
tion of this complex. Salicylic acid, butyrate and in-
domethacin also suppress the formation of the p50/
p50 homodimer, and may stimulate p50/RelA com-
plex formation. While our initial prediction was that
these agents would suppress NF-UB activation, the
¢nding that they alter the NF-UB subunit composi-
tion suggests a somewhat more complicated scenario
(although 2 and 4 mM butyrate do reproducibly sup-
press the total NF-UB DNA activity by up to 50%).
It is not presently clear how these di¡erent forms of
NF-UB function on speci¢c promoters: i.e., whether
they are stronger or weaker transcriptional activa-
tors, and whether there are di¡erent responses on
pro- and anti-death genes.
We also determined the e¡ect of the NSAIDs and
butyrate on NF-UB activated by Fas ligation. As
shown in Fig. 9, all three agents were found to en-
hance NF-UB activation induced by Fas (with sali-
cylic acid being notably weaker). Direct treatment
with H2O2 likewise enhances NF-UB activation by
Fas, suggesting that increased cellular ROS genera-
tion triggered by these agents contributes to this ac-
tivation. In the case of Fas treatment, all of the NF-
UB forms appear to be enhanced to a roughly equal
extent. The extent of this enhancement was approx-
imately 6-fold for H2O2, 9-fold for indomethacin and
20-fold for butyrate.
NF-UB plays a complex role in regulating pro-
grammed cell death. In many instances the inhibition
of NF-UB activity can sensitize cells to death in-
ducers, particularly TNF-K [44^48]. In other instan-
ces, however, NF-UB activation has been found to
play an important role in the induction of apoptosis
[49^51]. To obtain insight into the potential role of
NF-UB in HT-29 cell death, we determined the in£u-
ence of the antioxidant/NF-UB inhibitor NAC on
Fas- and TNF-K-induced HT-29 cell death. NAC
was chosen because of its demonstrated e¡ectiveness
at suppressing ROS generation by the chemopreven-
tive agents under study (Fig. 4 and [29]). As shown in
Fig. 10A, NAC suppressed cell death induced by
Fas, in the presence or absence of NSAID or buty-
rate (cells treated with Fas alone were incubated for
24 h instead of 16 h to obtain more extensive cell
death). The protection from Fas-induced cell killing
correlates with an inhibition of NF-UB activation
(Fig. 10C; the inhibition of NF-UB-DNA binding
is approximately 10-fold). This ¢nding is consistent
with a model in which NF-UB plays a role Fas-in-
duced HT-29 cell death. Additional experimentation
however is required to establish the role of this tran-
scription factor in this response.
The e¡ect of NAC on TNF-K-induced cell death
was also determined. As shown in Fig. 10B, NAC
partially suppresses cell death induced by the TNF-K
combination treatments. Interestingly, higher con-
centrations of NAC also increase TNF-K-induced
cell killing, even in the absence of chemopreventive
agent. The in£uence of NAC on TNF-K-induced
NF-UB was also determined (Fig. 10C). NAC was
found to enhance the formation of the c-Rel com-
plex, the NF-UB complex correlated with TNF-K-in-
duced cell death when cells were exposed to ROS-
generating agents (Fig. 8).
Since NAC partially suppresses cell death by the
TNF-K combination treatments, a role for ROS in
sensitizing HT-29 cells to TNF-K is supported (see
also Fig. 2). However, determining the role of NF-UB
in TNF-K-induced cell death is complicated by the
fact that NAC does not fully protect cells, and can
itself sensitize cells to TNF-K at higher concentra-
tions. One possibility is that the TNF-K sensitivity
Fig. 9. Salicylic acid, butyrate, indomethacin and H2O2 enhance
NF-UB activation by Fas ligating antibody. HT-29 cells were
treated with Fas ligating antibody alone (50 ng/ml) or Fas ligat-
ing antibody in the presence of the indicated concentrations of
salicylic acid (SA), butyrate (BA), indomethacin (IND) or
H2O2. Treatments were performed for 6 h, after which nuclear
extracts were prepared and analyzed for NF-UB DNA binding
activity by EMSA. Only protein-DNA complexes are shown.
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of the HT-29 cells is enhanced by increases or de-
creases in the cellular redox state, and that NF-UB is
an important sensor for changes in both directions.
Interpretation of this data is complicated by the fact
that NAC itself can generate ROS and other free
radicals under the proper conditions (i.e., in the pres-
ence of transition metals), and that such conditions
may be generated in the TNF-K stimulated cell [52].
An NAC-stimulated ROS generation was not how-
ever observed in TNF-K-treated cells by the H2DCF
oxidation assay in Fig. 4. Further study will be re-
quired to determine the relationship between cellular
redox, NF-UB activity and TNF-K-induced apoptosis
of HT-29 cells.
4. Discussion
We reported previously that the NSAIDs indometh-
acin and salicylic acid (and others) increase ROS
generation in HT-29 cells [29]. In addition, a number
of short chain fatty acids, including butyrate, also
have this e¡ect [29]. Here we show that this increased
ROS generation contributes to the sensitization of
these cells to apoptosis induced by TNF-K or Fas
ligation. Whether this increased ROS generation is
the only activity of these compounds relevant to
this sensitization remains to be determined. Evidence
that ROS do play a role in this sensitization comes
from the ¢nding that direct treatment of cell with
Fig. 10. (A) The e¡ect of NAC on Fas-induced apoptosis of HT-29 cells. Cells were preincubated with increasing NAC concentrations
for 4 h, after which time cells were treated with Fas ligating antibody alone (Fas*), or in combination with 8 mM salicylic acid
(Fas+SA), 4 mM butyrate (Fas+BA), or 200 WM indomethacin (Fas+IND). Cell death was determined as described in Fig. 1 after
16 h except for cells treated with Fas alone, which were counted after 24 h (to obtain higher levels of cell death). NAC concentrations
increase from left to right for each set and were 0, 3, 6, 12 and 24 mM. (B) The e¡ect of NAC on TNF-K induced cell death. Cells
were treated as in 10 A, except TNF-K was used instead of the anti-Fas antibody. Cell death was determined after 18 h. (C) The ef-
fect of NAC on NF-UB activated by Fas and TNF-K. HT-29 cells were preincubated with 0, 12 and 24 mM NAC for 4 h, after which
time anti-Fas antibody (K-Fas; 50 ng/ml) or TNF-K (100 ng/ml) were added to the cultures, as indicated. After a 6 h incubation, NF-
UB DNA binding activity was analyzed by EMSA.
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H2O2 can also sensitize them to Fas or TNF-K, and
that cell death by the combination treatments can be
suppressed by NAC (albeit partially for TNF-K-in-
duced apoptosis). The role of these cytokines in reg-
ulating cancer development is not entirely under-
stood, although their potential role in immune
surveillance of colonic tissue has been proposed.
The Fas ligand is utilized by T lymphocytes and
enhancement of its cell killing activity could facilitate
the immunogenic elimination of cancerous cells from
the colon [53]. It has also been found that colon
cancer cells are generally more resistant to Fas-in-
duced killing, suggesting that enhancing this activity
may improve cancer cell clearance [54]. The role of
TNF-K in regulating cancer development in the co-
lon is also not well understood, although high levels
of this cytokine in human tumors have been corre-
lated with longer patient survival [12]. It is also pos-
sible that ROS generation induced by these agents
sensitizes cells to other death inducers as well (e.g.,
TGF-L or other cytokines). Additional studies will be
required to determine the generality of this e¡ect.
ROS have been found to play a central role in
regulating apoptosis in numerous instances. Given
that reduced rates of apoptosis may contribute to
carcinogenesis [1], the regulation of cellular ROS
production may be an important variable in the de-
velopment of neoplasias. Other studies have also sug-
gested a potential role for ROS in cancer suppres-
sion. For example, the p53 tumor suppressor protein
activates the expression of ROS-generating proteins
that increase cellular ROS production and eventually
trigger apoptosis [14,55]. Increased ROS generation
by chemopreventive agents such as NSAIDs and bu-
tyrate may serve to compensate the lower levels of
ROS generation in p53 null cells. (HT-29 cell are p53
null [30].) Animal studies have also implicated ROS
in regulating carcinogenesis. Mice with elevated lev-
els of glutathione peroxidase are more sensitive to
skin carcinogenesis than their wild type counterparts
[56]. A similar correlation has been made in the co-
lon, where strains with higher levels of glutathione
peroxidase activity have a higher cancer risk [57].
The role of ROS in carcinogenesis is however likely
to be complex given the potential mutagenicity of
ROS. For example, the NSAID inhibition of cyclo-
oxygenase has been proposed to suppress carcino-
genesis by suppressing the production of peroxyl rad-
icals and the subsequent formation of mutagenic
lipid peroxidation breakdown products [25].
(Although the in£uence of NSAIDs reported here
appears to be distinct from their in£uence on lipid
peroxidation [29].) The role of ROS in carcinogenesis
may depend on the relative levels of di¡erent ROS
generated, and where and when they are present.
In many instances increasing ROS levels in the cell
are su⁄cient to trigger apoptosis. However, to obtain
apoptosis of HT-29 cells, TNF-K or a Fas ligating
antibody was required in addition to increased ROS
levels. Higher concentrations or longer incubation
times with the NSAIDs or H2O2 did lead to cell
death, but in these cases the appearance of the apop-
totic DNA ladder was not apparent. With longer
incubation times (2^4 days), butyrate was found to
enhance apoptosis, suggesting that butyrate may
have additional pro-death e¡ects on cells. In cells
where ROS rapidly trigger apoptosis, there may be
su⁄cient expression of Fas ligand, TNF-K or related
cell death machinery to support apoptosis. In this
regard, HT-29 cells may serve as useful model for
studying how ROS interact with events triggered by
death ligands such as TNF-K or Fas ligating anti-
bodies.
In studying the mechanism by which the NSAIDs
under study and butyrate in£uence cell death in HT-
29 cells, common e¡ects on the transcription factor
NF-UB were noted. Although none of these agents
activated NF-UB on their own, all were found to
enhance the formation of c-Rel-containing complexes
when applied to cells in combination with TNF-K. It
is not yet clear how this alteration in NF-UB subunit
composition in£uences gene expression patterns. In
the presence of Fas, all of the agents provided an
overall increase in NF-UB DNA binding activity.
The role of NF-UB in apoptosis is complex. In a
number of cases this transcription factor has been
found to suppress apoptosis [44^48], while in other
instances it is found to play an important role in
inducing apoptosis [49^51]. It has been proposed
that the in£uence of NF-UB on apoptosis may de-
pend on its subunit composition, and other cell-spe-
ci¢c variables [58]. Future studies will address the
role of speci¢c NF-UB subunits in HT-29 cell death.
Since cell death rates may contribute to cancer devel-
opment, determining the role of NF-UB (in its di¡er-
ent subunit compositions) in carcinogenesis is also of
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interest. In some cancers, constitutive NF-UB activa-
tion has been found to play a central role in gener-
ating a transformed phenotype [59,60]. Whether NF-
UB plays this role in colon carcinogenesis is not clear.
It has been found that activated ras and polyoma
middle T oncogenes reduce RelA expression in
Caco-2 [61]. In addition, we have observed lower
levels of p50 expression in cancerous and pre-cancer-
ous lesions in the mouse colon by immunohistochem-
ical staining (M.S. Inan, D. Wang, D. Rosenberg, C.
Giardina, unpublished data). NF-UB’s role in the co-
lon may therefore be more akin to its role in skin
development, where NF-UB serves primarily as a
growth repressor and its reduced activity results in
tissue hyperplasia [62]. Determining the role of NF-
UB in colon carcinogenesis could help guide the de-
velopment of improved chemoprevention and treat-
ment strategies.
While it is not clear whether the cellular responses
to NSAIDs and butyrate we describe here are oper-
ative in the colon, these ¢ndings establish a frame-
work through which in vivo experiments that test
these responses can be designed. Concerning the con-
centration of the agents used in our studies, butyrate
is present in the colon at concentrations close to
those used here [7], while NSAID concentrations em-
ployed were several-fold above pharmacological plas-
ma concentrations [63]. These NSAID concentra-
tions were employed to reproduce the in vivo
observation that NSAIDs enhance apoptosis in the
colon, and are similar to those employed by other
labs studying the in£uence of NSAIDs on apoptosis
in vitro [31,35]. Lower concentrations were also
found to enhance apoptosis (albeit at lower rates;
C. Giardina, unpublished data), and as noted by
others, relatively subtle di¡erences in apoptosis rates
can have signi¢cant consequences on tumor growth
when extrapolated over long periods of time [64].
Future experiments will assess the contribution of
the events identi¢ed in the cell culture model with
the ability of these agents to suppress colon carcino-
genesis in animals.
Acknowledgements
We thank Daniel Rosenberg and David Wang for
many enlightening discussions on carcinogenesis.
This work was supported by a grant from the Uni-
versity of Connecticut Research Foundation and a
Research Starter Grant from the Pharmaceutical Re-
search and Manufacturers Association of America
Foundation.
References
[1] A. Bedi, P.J. Pasricha, A.J. Akhtar, J.P. Barber, G.C. Bedi,
F.M. Giardiello, B.A. Zehnbauer, Cancer Res. 55 (1995)
1811^1816.
[2] M. Iwamoto, T. Koji, K. Makiyama, N. Kobayashi, P.K.
Nakane, J. Pathol. 180 (1996) 152^159.
[3] E. Ruoslahti, J.C. Reed, Cell 77 (1994) 477^478.
[4] S.M. Frisch, E. Ruoslahti, Curr. Opin. Cell Biol. 9 (1997)
701^706.
[5] C.Y. Wang, J.R. Eshleman, J.K.V. Willson, S. Markovitch,
Cancer Res. 55 (1995) 1101^1105.
[6] B.G. Heerdt, M.A. Houston, L.H. Augenlicht, Cancer Res.
54 (1994) 3288^3293.
[7] B. Singh, A.P. Halestrap, C. Paraskeva, Carcinogenesis 18
(1997) 1265^1270.
[8] A. McIntyre, P.R. Gibson, G.P. Young, Gut 34 (1993) 386^
391.
[9] P. Moller, K. Koretz, F. Leithauser, S. Bruderlein, C.
Henne, A. Quentmeier, P.H. Krammer, Int. J. Cancer 57
(1994) 371^377.
[10] J. Strater, I. Wellisch, S. Riedl, H. Walczak, K. Koretz, A.
Tandara, P.H. Krammer, P. Moller, Gastroenterology 113
(1997) 160^167.
[11] P.E. Watkins, B.F. Warren, S. Stephens, P. Ward, R.
Foulkes, Gut 40 (1997) 628^633.
[12] R.J. Barth, B.J. Camp, T.A. Martuscello, B.J. Dain, V.A.
Memoli, Cancer 78 (1996) 1168^1178.
[13] H. Ito, A. Yagita, M. Fujitsuka, Y. Atomi, I. Tatekawa,
Jpn. J. Cancer Res. 87 (1996) 1160^1164.
[14] K. Polyak, Y. Xia, J.L. Zweier, K.W. Kinzler, B. Vogelstein,
Nature 389 (1997) 300^305.
[15] A. Sanchez, A.M. Alvarez, M. Benito, I. Fabregat, J. Biol.
Chem. 271 (1996) 7416^7422.
[16] C. Langer, J.M. Jurgensmeier, G. Bauer, Exp. Cell Res. 222
(1996) 117^124.
[17] K.N. Islam, Y. Kayanoki, H. Kaneto, K. Suzuki, M. Asahi,
J. Fujii, N. Taniguchi, Free Radical Biol. Med. 22 (1997)
1007^1017.
[18] A.K. Talley, S. Dewhurst, S.W. Perry, S.C. Dollard, S.
Gummuluru, S.M. Fine, D. New, L.G. Epstein, H.E. Gen-
delman, H.A. Gelbard, Mol. Cell. Biol. 15 (1995) 2359^2366.
[19] D. Wallach, M. Boldin, E. Varfolomeev, R. Beyaert, P. Van-
denabeele, W. Fiers, FEBS Lett. 410 (1997) 96^106.
[20] Y. Kasahara, K. Iwai, A. Yachie, K. Ohta, A. Konno, H.
Seki, T. Miyawaki, N. Taniguchi, Blood 89 (1997) 1748^
1753.
[21] D.J. van den Dobbelsteen, C.S.I. Nobel, J. Schlegel, I.A.
BBAMCR 14423 5-1-99
C. Giardina et al. / Biochimica et Biophysica Acta 1448 (1999) 425^438 437
Cotgreave, S. Orrenius, A.F.G. Slater, J. Biol. Chem. 271
(1996) 15420^15427.
[22] H.D. Um, J.M. Orenstein, S.M. Wahl, J. Immunol. 156
(1996) 3469^3477.
[23] L. Gamet, D. Daviaud, C. Denis-Pouxviel, C. Remesy, J.C.
Murat, Int. J. Cancer 52 (1992) 286^289.
[24] J.A. Barnard, G. Warwick, Cell Growth Di¡er. 4 (1993)
495^501.
[25] G.N. Levy, FASEB J. 11 (1997) 234^247.
[26] L.S. Simon, Curr. Opin. Rheumatol. 5 (1993) 265^275.
[27] A. Hague, G.D. Diaz, D.J. Hicks, S. Krawjewski, J.C. Reed,
C. Paraskeva, Int. J. Cancer 72 (1997) 898^905.
[28] M. Mandal, X. Wu, R. Kumar, Carcinogenesis 18 (1997)
229^232.
[29] C. Giardina, M.S. Inan, Biochim. Biophys. Acta 1401 (1998)
277^288.
[30] N.K. Ossina, A. Cannas, V.C. Powers, P.A. Fitzpatrick, J.D.
Knight, J.R. Gilbert, E.M. Shekhtman, L.D. Tomei, S.R.
Umansky, M.C. Kiefer, J. Biol. Chem. 272 (1997) 16351^
16357.
[31] D.J. Elder, A. Hague, D.J. Hicks, C. Paraskeva, Cancer Res.
56 (1996) 2273^2276.
[32] S. Schutze, K. Pottho¡, T. Machleidt, D. Berkovic, K. Weig-
mann, M. Kronke, Cell 71 (1992) 765^776.
[33] Y. Suzuki, Y. Ono, Y. Hirabayashi, FEBS Lett. 425 (1998)
209^212.
[34] S.F. Moss, B. Agarwal, N. Arber, R.J. Guan, M. Krajewska,
S. Krajewski, J.C. Reed, P.R. Holt, Biochem. Biophys. Res.
Commun. 223 (1996) 199^203.
[35] X. Lu, D.W. Fairbairn, W.S. Bradshaw, K.L. O’Neill, D.L.
Ewert, D.L. Simmons, Prostaglandins 54 (1997) 549^568.
[36] K.M. Herold, P.G. Rothberg, Oncogene 3 (1988) 423^428.
[37] M.K.A. Bauer, M. Vogt, M. Los, J. Siegel, S. Wesselborg,
K. Schulze-Ostho¡, J. Biol. Chem. 273 (1998) 8048^8055.
[38] F.J. Casano, A.M. Rolando, J.S. Mudgett, S.M. Molineaux,
Genomics 20 (1994) 474^481.
[39] H. Wu, G. Lozano, J. Biol. Chem. 269 (1994) 20067^20074.
[40] G.H. Wong, J.H. Elwell, L.W. Oberley, D.V. Goeddel, Cell
58 (1989) 923^931.
[41] A.W.J. Opipari, H.M. Hu, R. Yabkowitz, V.M. Dixit,
J. Biol. Chem. 267 (1992) 12424^12427.
[42] K.N. Schmidt, P. Amstad, P. Cerutti, P.A. Baeuerle, Chem.
Biol. 2 (1995) 13^21.
[43] S. Mihm, D. Galter, W. Droge, FASEB J. 9 (1995) 246^252.
[44] R.E. Bellas, M.J. Fitzgerald, N. Fausto, G.E. Sonenshein,
Am. J. Pathol. 151 (1997) 891^896.
[45] M. Wu, H. Lee, R.E. Bellas, S.L. Schauer, M. Arsura, D.
Katz, M.J. FitzGerald, T.L. Rothstein, D.H. Sherr, G.E.
Sonenshein, EMBO J. 15 (1996) 4682^4690.
[46] A.A. Beg, W.C. Sha, R.T. Bronson, S. Ghosh, D. Baltimore,
Nature 376 (1995) 167^170.
[47] A.A. Beg, D. Baltimore, Science 274 (1996) 782^784.
[48] D.J. VanAntwerp, S.J. Martin, T. Kafri, D.R. Green, I.M.
Verma, Science 274 (1996) 787^789.
[49] K.-I. Lin, S.-H. Lee, R. Narayanan, J.M. Baraban, J.M.
Hardwick, R.R. Ratan, J. Cell Biol. 131 (1995) 1149^1161.
[50] S. Grimm, M.K.A. Bauer, P.A. Baeuerle, K. Schulze-Ost-
ho¡, J. Cell Biol. 134 (1996) 13^23.
[51] M. Grilli, M. Pizzi, M. Memo, P.F. Spano, Science 274
(1996) 1383^1385.
[52] H.P. Misra, J. Biol. Chem. 249 (1974) 2151^2155.
[53] R. DeMaria, M. Boirivant, M.G. Cifone, P. Roncaioli, M.
Hahne, J. Tschopp, F. Pallone, A. Santoni, R. Testi, J. Clin.
Invest. 97 (1996) 316^322.
[54] U. von Reyher, J. Strater, W. Kittstein, M. Gschwendt, P.H.
Krammer, P. Moller, Cancer Res. 58 (1998) 526^534.
[55] T.M. Johnson, Z.X. Yu, V.J. Ferrans, R.A. Lowenstein, T.
Finkel, Proc. Natl. Acad. Sci. USA 93 (1996) 11848^11852.
[56] Y.P. Lu, Y.R. Lou, H.L. Newmark, O.I. Mirochnitchenko,
M. Inouye, M.T. Huang, Cancer Res. 57 (1997) 1468^1474.
[57] F.F. Chu, R.S. Esworthy, Y.S. Ho, M. Bermeister, K. Swe-
derek, R.W. Elliott, Biomed. Environ. Sci. 10 (1997) 156^
162.
[58] V.R. Baichwal, P.A. Baeuerle, Curr. Biol. 7 (1997) R94^R96.
[59] R.C. Bargou, F. Emmerich, D. Krappmann, K. Bommert,
M.Y. Mapara, W. Arnold, H.D. Royer, E. Grinstein, A.
Greiner, C. Scheidereit, B. Dorken, J. Clin. Invest. 100
(1997) 2961^2969.
[60] J.Y. Reuther, G.W. Reuther, D. Cortez, A.M. Pendergast,
J.A.S. Baldwin, Genes Dev. 12 (1998) 968^981.
[61] A. Cadoret, F. Bertrand, S. Baron-Delage, P. Levy, G.
Courtois, C. Gespach, J. Capeau, G. Cherqui, Oncogene
14 (1997) 1589^1600.
[62] C.S. Seitz, Q. Lin, H. Deng, P.H. Khavari, Proc. Natl. Acad.
Sci. USA 95 (1998) 2307^2312.
[63] J. Vane, R. Botting, FASEB J. 1 (1987) 89^96.
[64] W. Bursch, S. Pa¡e, B. Putz, G. Barthel, R. Schulte-Her-
mann, Carcinogenesis 11 (1990) 847^853.
BBAMCR 14423 5-1-99
C. Giardina et al. / Biochimica et Biophysica Acta 1448 (1999) 425^438438
